FDA approves maraviroc

Roehr, Bob
August 2007
Bay Area Reporter;8/9/2007, Vol. 37 Issue 32, p17
The article reports that the U.S. Food and Drug Administration (FDA) has approved Pfizer's Maraviroc, the first anti-HIV drug that targets the CCR5 coreceptor on the outside of the cell. The drug, under the trade name Selzentry, has been approved for use in treatment experienced patients. The FDA recommends that the drug be used after a test has been done to determine that the patient only has virus using the CCR5 coreceptor.


Related Articles

  • Trends in the prescription drug plans delivering the Medicare Part D Prescription Drug Benefit. Brill, Joel V. // American Journal of Health-System Pharmacy;8/1/2007 Supplement, Vol. 64, pS3 

    Purpose. The potential impact of the Democrat-proposed Medicare drug program reform plan; possible Congressional actions in 2007; the standard Medicare prescription drug benefit; the use of low-income subsidies (LIS); and trends in 2006 and 2007 Medicare prescription drug plan (PDP) offerings,...

  • New drugs and dosage forms.  // American Journal of Health-System Pharmacy;7/1/2006, Vol. 63 Issue 13, p1218 

    No abstract available.

  • Novel HIV treatment approved. Groeschen, Heather M.; Provost, George P. // American Journal of Health-System Pharmacy;9/15/2007, Vol. 64 Issue 18, p1886 

    The article reports on the announcement made by the U.S. Food and Drug Administration and Pfizer Inc. on the approval of Selzentry or maraviroc in August 2007. Selzentry is the first agent in a class of oral human immunodeficiency virus (HIV) medications such as chemokine receptor 5 (CCR5)...

  • FDA panel OKs new class of HIV drug. Roehr, Bob // Bay Area Reporter;4/26/2007, Vol. 37 Issue 17, p17 

    The article reports that a committee of the U.S. Food and Drug Administration has recommended approval of Pfizer Inc.'s CCR5 inhibitor maraviroc, trademarked Celsentri. Maraviroc belongs to a class of anti-HIV drugs developed for heavily treatment-experienced patients. It works against the R5...

  • Maraviroc: A coreceptor CCR5 antagonist for management of HIV infection. Yost, Raymond; Pasquale, Timothy R.; Sahloff, Eric G. // American Journal of Health-System Pharmacy;4/15/2009, Vol. 66 Issue 8, p715 

    Purpose. The mechanism of action, pharmacology, pharmacokinetics, clinical efficacy, drug interactions, adverse effects, dosage and administration, cost, and role in therapy of maraviroc are reviewed. Summary. Maraviroc is the first CCR5 coreceptor antagonist to receive marketing approval from...

  • 2003 approvals: a year of innovation and upward trends. Frantz, Simon // Nature Reviews Drug Discovery;Feb2004, Vol. 3 Issue 2, p103 

    Assesses the quality and value of new drugs approved by the U.S. Food and Drug Administration (FDA) and the European Agency for the Evaluation of Medicinal Products (EMEA) in 2003. Increase in the number of new molecular entities (NMEs), more popularly known as drugs, approved by the FDA and...

  • U.S. FDA Grants Priority Review for Truvada(r) for Reducing the Risk of Acquiring HIV Infection.  // Biomedical Market Newsletter;2/14/2012, Vol. 21, p1 

    The article offers information related to an announcement made by Gilead Sciences Inc. regarding acceptance and approval of its supplemental New Drug Application by the U.S. Food and Drug Administration. Truvada, a registered trademark of Gilead Sciences Inc. is the first agent which is...

  • 2 more antiretrovirals added to AIDS relief plan.  // Contemporary Pediatrics;Sep2007, Vol. 24 Issue 9, p18 

    The article reports on the tentative approval given by the U.S. Food and Drug Administration (FDA) to the 50th and 51st drugs to fight the HIV/AIDS pandemic under the President's Emergency Plan for AIDS Relief or PEPFAR. A generic, fixed-dose, triple-combination antiretroviral for pediatric use...

  • Is Resistance to Dolutegravir Possible When This Drug Is Used in First-Line Therapy? Mespl├Ęde, Thibault; Wainberg, Mark A. // Viruses (1999-4915);Sep2014, Vol. 6 Issue 9, p3377 

    Dolutegravir (DTG) is an HIV integrase inhibitor that was recently approved for therapy by the Food and Drug Administration in the United States. When used as part of first-line therapy, DTG is the only HIV drug that has not selected for resistance mutations in the clinic. We believe that this...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics